Amarin Corporation Reports 17% Revenue Growth in Q3 2025, Net Loss Improves

Amarin Corporation plc reported its financial results for the third quarter of 2025, revealing total revenue of $49.7 million, a 17% increase from $42.3 million in the same period last year. The growth was primarily driven by a $10.3 million rise in U.S. product revenue, which reached $40.9 million, attributed to an increase in net selling prices following the company's exit from the Medicaid and 340B programs. However, the company experienced a decline in international product revenue, which fell to $4.1 million from $4.3 million year-over-year, and revenue from the rest of the world decreased to $3.6 million from $6.9 million.

For the nine months ending September 30, 2025, Amarin's total revenue was $164.4 million, slightly down from $166.3 million in the prior year. The decrease was mainly due to an 8% drop in U.S. product revenue, which totaled $113.0 million compared to $122.5 million in 2024. In contrast, licensing and royalty revenue increased by 30% to $28.2 million, bolstered by a $25 million upfront payment from a licensing agreement with Recordati. The company’s gross margin improved to 51% for the nine-month period, up from 48% in the previous year, reflecting a favorable change in customer mix.

Amarin's operating expenses for the third quarter were $33.3 million, down from $41.4 million in the same quarter of 2024, largely due to a significant reduction in selling, general, and administrative expenses, which fell by 47% to $19.7 million. This reduction was primarily a result of the Global Restructuring Plan initiated in June 2025, which aimed to streamline operations and reduce costs. The company reported a net loss of $7.7 million for the quarter, a notable improvement from a loss of $25.1 million in the prior year.

As of September 30, 2025, Amarin's total assets amounted to $659.8 million, with cash and cash equivalents of $122.8 million and short-term investments of $163.8 million. The company had no outstanding debt and reported an accumulated deficit of $1.7 billion. The restructuring plan is expected to yield annual cost savings of approximately $70 million, primarily through the elimination of commercial roles in Europe.

Looking ahead, Amarin remains focused on maintaining its market leadership in the U.S. while expanding access to VASCEPA through its international partnerships. The company anticipates continued variability in quarterly cash flows due to factors such as API purchases and the competitive landscape in the U.S. market. Amarin's management believes that its current cash and investments will be sufficient to support operations for at least the next year, although they acknowledge the inherent risks and uncertainties that could impact this outlook.